Clinically Meaningful Within-Patient Change in Core Attention-Deficit/Hyperactivity Disorder Symptoms in Children and Adolescents Treated With Centanafadine: Results From Two Phase 3 Randomized Clinical Trials

BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) is characterized by core symptoms of inattention, hyperactivity, and impulsivity that are persistent and can interfere with daily functioning. Centanafadine is a norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) and cental nervous symstem simulant recently FDA approved for the treatment of ADHD in both adult and pediatric patients. This secondary analysis explores the efficacy of centanafadine for the treatment of ADHD…

via https://pubmed.ncbi.nlm.nih.gov/42779129/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1HYeX0emtvYgH07Wkz0a8n9otrdMd-JIklc_uo0I5vh1u9WMEy&fc=None&ff=20260925010807&v=2.20.1